紫杉醇联合顺铂新辅助化疗对晚期宫颈癌患者淋巴结转移率及远期预后的影响

doi:10.3969/j.issn.1006-6233.2019.02.012

摘要
图/表
参考文献
相关文章 (8)

全文: PDF (1270 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:分析紫杉醇联合顺铂新辅助化疗对晚期宫颈癌患者淋巴结转移率及远期预后的影响。方法:选取本院78例晚期宫颈癌患者,均行广泛子宫切除及盆腔淋巴结清扫术,随机分为对照组与研究组各39例。对照组术前采用顺铂+亚叶酸钙+氟脲苷+多柔比星的治疗方案,而研究组术前采用紫杉醇联合顺铂新辅助化疗方案,对比两组治疗后淋巴结转移率及远期预后情况。结果:研究组治疗总有效率高于与对照组(P<0.05);研究组淋巴结转移率、脉管浸润率、宫旁累及率均较对照组低(P<0.05);两组不良反应发生率对比并无明显差异(P>0.05);研究组3年生存率、中位生存期均较对照组高(P<0.05)。结论:术前应用紫杉醇联合顺铂新辅助化疗可明显减轻晚期宫颈癌患者淋巴结转移率,减少病灶范围,提高患者近期疗效,有助于提高患者远期生存率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	向安玲
	庄瑞春
	彭玲

关键词 ：紫杉醇, 顺铂, 新辅助化疗, 晚期宫颈癌

Abstract：Objective: To analyze the effects of neoadjuvant chemotherapy with paclitaxel and cisplatin on lymph node metastasis and long term of prognosis in patients with advanced cervical cancer. Methods: 78 cases of advanced cervical cancer who underwent radical hysterectomy and pelvic lymph node dissection were selected in our hospital and were randomly divided into the control group and study group, with 39 cases in each group. The control group underwent the treatment program of cisplatin, leucovorin calcium, fluorouracil glucoside and doxorubicin before surgery, and the study group were treated with neoadjuvant chemotherapy with paclitaxel and cisplatin before surgery. The rate of lymph node metastasis and long term of prognosis were compared between the two groups after treatment. Results:The total efficiency of the study group was higher than that of the control group (P<0.05); the rate of lymph node metastasis, vascular invasion, parametrial involvement in the study group were lower than those in the control group (P<0.05); the incidence rate of adverse reactions of the two groups showed no different significance (P>0.05); the survival rate of 3 years and median survival time in the study group were higher than those in the control group (P<0.05). Conclusion: Neoadjuvant chemotherapy of paclitaxel combined with cisplatin can significantly reduce the rate of lymph node metastasis in patients with advanced cervical cancer before operation and reduce the range of lesions, which can improve the clinical effects and help to improve the long-term of survival rate.

Key words： Paclitaxel Cisplatin Neoadjuvant chemotherapy Advanced cervical cancer

基金资助:重庆卫生和计划生育委员会科技项目,(编号:2015-2-126)

通讯作者: 庄瑞春

引用本文:

向安玲, 庄瑞春, 彭玲. 紫杉醇联合顺铂新辅助化疗对晚期宫颈癌患者淋巴结转移率及远期预后的影响[J]. 河北医学, 2019, 25(2): 219-222.
XIANG Anling, ZHUANG Ruichun, PENG Ling. Effects of Neoadjuvant Chemotherapy with Paclitaxel and Cisplatin on Lymph Node Metastasis and Long Term of Prognosis in Patients with Advanced Cervical Cancer. HeBei Med, 2019, 25(2): 219-222.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2019.02.012 或 http://www.hbyxzzs.cn/CN/Y2019/V25/I2/219

[1] 刘少晓,程晓燕,郑红枫,等.紫杉醇联合顺铂新辅助治疗局部晚期宫颈癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(6):432~434.
[2] Thaker PH, Salani R, Brady WE, et al. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)[J]. Ann Oncol,2017,28(3):505~511.
[3] 覃小敏,李琳,黄艳丽,等.中老年宫颈癌患者预后相关影响因素的分析[J].癌症进展,2015,13(3):346~349.
[4] Wang HY, Yao ZH, Tang H, et al. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma[J]. Oncotarget,2017,8(5):7540~7547.
[5] 王婉,胡倩倩,张伟,等.伊立替康联合顺铂与紫杉醇联合顺铂治疗宫颈癌的临床疗效分析[J].中国妇幼健康研究,2017,28(01):84~87.
[6] Asano H, Todo Y, Watari H. Adjuvant chemotherapy for early-stage cervical cancer[J]. Chin Cancer Res,2016,28(2):228~234.
[7] 万晓丽,罗晓,夏秀英,等.局部晚期宫颈癌术前新辅助化疗疗效观察[J].临床军医杂志,2016,44(10):1066~1069.
[8] Kleinberg LR, Catalano PJ, Forastiere AA, et al. Eastern cooperative oncology group and american college of radiology imaging network randomized phase 2 trial of neoadjuvant preoperative paclitaxel/cisplatin/radiation therapy (RT) or irinotecan/cisplatin/RT in esophageal adenocarcinoma: long-term outcome and implications for trial design[J]. Int Radiat Oncol Biol Phys,2016,94(4):738~746.
[9] Tsuda N, Watari H, Ushijima K. Chemotherapy and molecular targeting therapy for recurrent cervical cancer[J]. Chin Cancer Res,2016,28(2):241~253.
[10] 徐丽伟,张梦真.宫颈癌和宫颈上皮内瘤变组织中成纤维活化蛋白α的表达[J].郑州大学学报:医学版,2015,50(3):375~377.
[11] Elias ST, Borges GA, Rego DF, et al. Combined paclitaxel, cisplatin and fluorouracil therapy enhances ionizing radiation effects, inhibits migration and induces G0/G1 cell cycle arrest and apoptosis in oral carcinoma cell lines[J]. Oncol Lett, 2015,10(3):1721~1727.
[12] Zhao H, Li L, Su H, et al. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study[J]. Oncotarget,2016,7(43):70969~70978.